Literature DB >> 30057416

Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401.

Lukasz Kuryk1,2, Anne-Sophie W Møller3, Magnus Jaderberg3.   

Abstract

Adaptive immunity involves activation of T cells via antigen presentation by antigen presenting cells (APCs) along with the action of co-stimulatory molecules and pattern recognition receptors. Cluster of differentiation 40 (CD40) is one such costimulatory molecule that is expressed on APCs that binds to CD40 ligand (CD40L) on T helper cells and activates a signaling cascade, subsequently resulting in a wide range of immune and inflammatory responses. Considering its important role in regulation of immune response, CD40/40 L has been used for developing antitumor vaccines. In this study, we developed methods for evaluating and quantifying the activity of CD40L expressed from an adenovirus vector ONCOS-401. Our results show that the ONCOS-401 vector produces functional CD40L, which can bind and activate a NF-κB-dependent signaling cascade, leading to secreted embryonic alkaline phosphatase reporter production in HEK293-BLUE cells. In addition, quantification of CD40L production using enzyme-linked immunosorbent assay and HEK-293 BLUE reporter cells showed reproducibly higher recovery of CD40L from ONCOS-401 than from the negative control vector or uninfected cells with consistent inter and intra-assay precision. Thus, a rapid and easy method for quantifying and assessing CD40L production and activity from adenovirus vectors would support the assessment of efficacy of the vector for gene therapy - this was the objective of our study.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30057416     DOI: 10.1038/s41417-018-0038-x

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  10 in total

Review 1.  Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.

Authors:  Lukasz Kuryk; Giulia Rodella; Monika Staniszewska; Katarzyna Wanda Pancer; Magdalena Wieczorek; Stefano Salmaso; Paolo Caliceti; Mariangela Garofalo
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

2.  Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma.

Authors:  Lukasz Kuryk; Anne-Sophie W Møller; Magnus Jaderberg
Journal:  J Med Virol       Date:  2019-06-24       Impact factor: 2.327

3.  Heterologous and cross-species tropism of cancer-derived extracellular vesicles.

Authors:  Mariangela Garofalo; Alessandro Villa; Daniela Crescenti; Monica Marzagalli; Lukasz Kuryk; Patrizia Limonta; Vincenzo Mazzaferro; Paolo Ciana
Journal:  Theranostics       Date:  2019-08-09       Impact factor: 11.556

4.  Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model.

Authors:  Mariangela Garofalo; Laura Bertinato; Monika Staniszewska; Magdalena Wieczorek; Stefano Salmaso; Silke Schrom; Beate Rinner; Katarzyna Wanda Pancer; Lukasz Kuryk
Journal:  Pharmaceutics       Date:  2021-04-14       Impact factor: 6.321

5.  From Immunosuppression to Immunomodulation - Turning Cold Tumours into Hot.

Authors:  Mariangela Garofalo; Katarzyna Wanda Pancer; Magdalena Wieczorek; Monika Staniszewska; Stefano Salmaso; Paolo Caliceti; Lukasz Kuryk
Journal:  J Cancer       Date:  2022-07-04       Impact factor: 4.478

6.  Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2.

Authors:  Mariangela Garofalo; Monika Staniszewska; Stefano Salmaso; Paolo Caliceti; Katarzyna Wanda Pancer; Magdalena Wieczorek; Lukasz Kuryk
Journal:  Vaccines (Basel)       Date:  2020-06-10

7.  Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks.

Authors:  Lukasz Kuryk; Anne-Sophie W Møller; Antti Vuolanto; Sari Pesonen; Mariangela Garofalo; Vincenzo Cerullo; Magnus Jaderberg
Journal:  Int J Mol Sci       Date:  2019-01-31       Impact factor: 5.923

Review 8.  How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs.

Authors:  Mariangela Garofalo; Giovanni Grazioso; Andrea Cavalli; Jacopo Sgrignani
Journal:  Molecules       Date:  2020-04-10       Impact factor: 4.411

9.  Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor.

Authors:  Lukasz Kuryk; Anne-Sophie W Møller
Journal:  J Med Virol       Date:  2020-02-03       Impact factor: 2.327

10.  Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells.

Authors:  Mariangela Garofalo; Federica Bellato; Salvatore Magliocca; Alessio Malfanti; Lukasz Kuryk; Beate Rinner; Samuele Negro; Stefano Salmaso; Paolo Caliceti; Francesca Mastrotto
Journal:  Pharmaceutics       Date:  2021-06-24       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.